Published in: Journal of Biomedical Optics Authors: Khaled Ramadan, Tina Saeidi, Edson Brambate, Vanderlei Bagnato, Marcelo Cypel, Lothar Lilge
Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable
ML7710 for photoactivated treatment of lung cancer Read More »
Motivation While Photofrin PDT is an approved oncological therapy for multiple indications, its wider use is hindered by prolonged skin photosensitivity lasting several weeks. The aim of this study is to investigate intratumoral Photofrin administration as a way to decrease skin photosensitivity compared to the standard IV injection protocol. Tumor necrosis after PDT was
Optimizing photosensitizer administration for cancer therapy Read More »
Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues
Development of heat shock protein 90-targeted PDT for inflammatory breast cancer Read More »
Presented in: SPIE BIOS 2021 Authors: Zoe Ylöniemi, Johannes Kivelä, Elias Kokko, Robert Perttilä, Visa Kaivosoja, Lasse Orsila, Petteri Uusimaa
